Journal article
Phase II trial of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study.
Abstract
PURPOSE: This multicenter phase II trial investigated the efficacy and toxicity of a combination of the novel intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl (DPPE), and doxorubicin in patients with anthracycline-naïve metastatic breast cancer. Preclinical models and early single institutional studies suggested DPPE could potentiate the cytotoxicity of doxorubicin.
PATIENTS AND METHODS: Forty-two women, …
Authors
Khoo K; Brandes L; Reyno L; Arnold A; Dent S; Vandenberg T; Lebwohl D; Fisher B; Eisenhauer E
Journal
Journal of Clinical Oncology, Vol. 17, No. 11, pp. 3431–3437
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
November 1999
DOI
10.1200/jco.1999.17.11.3431
ISSN
0732-183X